Error message

  • Deprecated function: Return type of DateObject::__wakeup() should either be compatible with DateTime::__wakeup(): void, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in include_once() (line 143 of /local/drupal/proteomics/sites/default/modules/date/date_api/date_api.module).
  • Deprecated function: Return type of DateObject::format($format, $force = false) should either be compatible with DateTime::format(string $format): string, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in include_once() (line 143 of /local/drupal/proteomics/sites/default/modules/date/date_api/date_api.module).
  • Deprecated function: Return type of DateObject::setTimezone($tz, $force = false) should either be compatible with DateTime::setTimezone(DateTimeZone $timezone): DateTime, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in include_once() (line 143 of /local/drupal/proteomics/sites/default/modules/date/date_api/date_api.module).
  • Deprecated function: Optional parameter $input declared before required parameter $form_state is implicitly treated as a required parameter in include_once() (line 1439 of /local/drupal/proteomics/includes/bootstrap.inc).
  • Deprecated function: Optional parameter $input declared before required parameter $form_state is implicitly treated as a required parameter in require_once() (line 12 of /local/drupal/proteomics/sites/default/modules/media/media.module).
  • Deprecated function: Optional parameter $module_name declared before required parameter $data is implicitly treated as a required parameter in require_once() (line 18 of /local/drupal/proteomics/sites/default/modules/media/modules/media_wysiwyg/media_wysiwyg.module).
  • Deprecated function: Optional parameter $view_mode declared before required parameter $langcode is implicitly treated as a required parameter in include_once() (line 1439 of /local/drupal/proteomics/includes/bootstrap.inc).
  • Deprecated function: Optional parameter $item declared before required parameter $complete_form is implicitly treated as a required parameter in include_once() (line 1439 of /local/drupal/proteomics/includes/bootstrap.inc).
  • Deprecated function: Optional parameter $base_table declared before required parameter $options is implicitly treated as a required parameter in include_once() (line 3542 of /local/drupal/proteomics/includes/bootstrap.inc).
  • Deprecated function: Optional parameter $base_field declared before required parameter $options is implicitly treated as a required parameter in include_once() (line 3542 of /local/drupal/proteomics/includes/bootstrap.inc).
×

COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, advance proteome and proteogenome science and technology development through community resources (data and reagent), and accelerate the translation of molecular findings into the clinic. This is achieved through OCCPR-supported programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, and collaborations with international organizations/institutions.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

CPTAC Data Used to Develop Cutting Edge Tools for Illuminating the Druggable Genome

Recently, Dr. Bing Zhang and his team from the Lester and Sue Smith Breast Center at Baylor College of Medicine were awarded a two-year funding opportunity to develop Cutting Edge Informatics Tools for the NIH Common Fund program Illuminating the Druggable Genome (IDG).


CPTAC Researchers Document Differential Expression of Glycosylation Sites in Liver and Pancreatic Cancer

Core fucosylation (CF) of N-linked glycoproteins is linked with the functions of glycoproteins in many physiological and pathological processes. This feature has a high potential for use in the detection of cancer as well as the development of targeted therapies. For example, high levels of alpha-...


FDA and NIH Sign Memorandum of Understanding: Interagency Collaboration to Advance Proteogenomics Research

The National Cancer Institute (NCI) of the National Institutes of Health is pleased to announce the signing of a memorandum of understanding (MOU) bolstering its ongoing collaboration with the U.S. Food and Drug Administration (FDA). This MOU provides a framework that will enable and encourage the...


Ex Vivo Drug Sensitivity Testing in AML: Improving Response Predictability Using Proteomic Measurements

Genetic heterogeneity amongst leukemic cells is a major contributor to low survival rates and poor clinical outcomes for patients with acute myeloid leukemia (AML). This diversity drives complex signaling pathways at the protein level which necessitate individualized treatment protocols for each...


CPTAC Investigators Analyze Proteogenomic Markers of Chemotherapy Resistance and Response in Triple Negative Breast Cancer

CPTAC investigators from Baylor College of Medicine and the Broad Institute of MIT and Harvard in collaboration with oncologists at Washington University in St. Louis have identified biological markers in triple negative breast cancer (TNBC) that are associated with resistance to chemotherapy...


Collaborating with Major International Partners - NCI Welcomes Renewed Commitments to the Cancer Moonshot with Australia, Canada, and Germany

The National Cancer Institute (NCI) of the National Institutes of Health is pleased to announce the renewal of partnerships with Australia, Canada, and Germany. These partnerships, through memoranda of understanding (MOUs) to the NCI Cancer Moonshot International...


CPTAC Collaborates with the NIH Common Fund: Over 490 New Assays Released to the Public

CPTAC investigators from Washington University School of Medicine in St. Louis have developed new multiplexed assays for analyzing kinase proteins by parallel reaction monitoring mass spectrometry (PRM), a targeted form of mass spectrometry that enables highly sensitive and specific measurements. The...


NCI's CPTAC and PDC Recognized by FedHealthIT for Outstanding Commitment to Excellence and Innovation

This year, the 8th Annual FedHealthIT Innovation Awards recognized programs from the Department of Veterans Affairs, Military Health, Health and Human Services, and Centers for Medicare and Medicaid Services. These programs were carefully selected by their peers for their commitment to excellence,...


CellCarta Will Offer MRM-based Assay Services Using CPTAC Assays Developed at the Fred Hutchinson Cancer Center

In May, a leading provider of precision medicine laboratory services, CellCarta, acquired the commercial rights to the CPTAC-qualified antibody panels and assays developed by the Paulovich laboratory at Fred Hutchinson Cancer Center; they produce high-end multiplex quantitative immuno-MRM mass...


CPTAC Announces New PCC, PGDAC, and PTRC Teams

This month, the Office of Cancer Clinical Proteomics Research (OCCPR) at the National Cancer Institute (NCI), part of the National Institutes of Health, has reaffirmed its commitment to furthering proteogenomics research by announcing the next round of Proteome Characterization Center (PCC; RFA-CA-21...


Pages